#Sweden #Stockholm #Sobi #gout #NASP

Sobi's NASP Conference Call on Uncontrolled Gout

Introduction
Sobi (Swedish Orphan Biovitrum AB) has recently made pivotal strides in treating uncontrolled gout with its innovative program, NASP, previously named SEL-212. As part of its ongoing commitment to transparency and stakeholder engagement, Sobi is hosting a conference call that invites investors, analysts, and media representatives to gain key insights into this promising therapeutic approach.

Event Details
The conference call is scheduled for September 16, 2025, at 16:30 CEST (Central European Summer Time), 15:30 BST (British Summer Time), and 10:30 EDT (Eastern Daylight Time). During this session, esteemed management representative Dr. Herbert Baraf will discuss the nuances of the NASP program, particularly following the recent acceptance of the filing submission by the US FDA for treating uncontrolled gout.

How to Access the Call
Participants can join the call using the following dial-in numbers:

• - Sweden: +46 8 5051 0031
• - United Kingdom: +44 207 107 06 13
• - United States: +1 631 570 56 13

For attendees from other countries, specific dial-in details are available on the Sobi website. Furthermore, the presentation will be available live on sobi.com, with accompanying slides published before the call for pre-event perusal.

Why This Matters
Uncontrolled gout poses significant challenges for those affected, leading to recurrent flares and debilitating pain. Sobi's innovative solutions, aimed at tackling these complications, hold the promise of significantly improving the quality of life for patients. The NASP program represents an important advancement in addressing the unmet medical needs within this disease landscape.

About Sobi
Sobi is a global biopharmaceutical company dedicated to transforming the lives of patients with rare diseases through innovative treatments. With a workforce of around 1,900 employees spread across Europe, North America, the Middle East, Asia, and Australia, Sobi stands at the forefront of medical innovation. In 2024, the company's revenue reached an impressive SEK 26 billion, reflecting its robust growth and commitment to patient care. Sobi's shares are listed on Nasdaq Stockholm under the ticker symbol STOSOBI.

Conclusion
This conference call serves as a vital platform for stakeholders to engage with Sobi's leadership and gain insights into the future of gout treatment. As the date approaches, interested parties are encouraged to mark their calendars and prepare for what promises to be an enlightening discussion on the NASP program and its implications for patients suffering from uncontrolled gout. For media inquiries or further information, Sobi's Investor Relations team is available to provide assistance.

Stay updated by visiting sobi.com for further details on the conference call and ongoing developments in Sobi's drug pipeline.